Nitroimidazole antimicrobial

This page covers all Nitroimidazole antimicrobial drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial/protozoal DNA, Bacterial DNA (via nitroimidazole reduction), Bacterial and parasitic DNA.

Targets

Bacterial/protozoal DNA · Bacterial DNA (via nitroimidazole reduction) · Bacterial and parasitic DNA · Bacterial/parasitic DNA · Microbial DNA (non-selective)

Marketed (6)

• Metronidazole Vaginal · Peking University Shenzhen Hospital · Infectious Disease
  Metronidazole is a nitroimidazole antimicrobial that disrupts bacterial and protozoal DNA, leading to cell death.
• Topical metronidazole · University of Toronto · Dermatology
  Topical metronidazole reduces inflammation and bacterial overgrowth in skin conditions by disrupting microbial DNA and reducing pro-inflammatory cytokine production.
• Metronidazole 250 (7 days) · University of Guarulhos · Infectious Disease
  Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material.
• Metronidazole Topical Gel 2% · Jinnah Postgraduate Medical Centre · Dermatology
  Metronidazole disrupts bacterial and protozoal DNA, causing cell death and reducing inflammation in topical infections.
• Metronidazole gel 1% · Galderma R&D · Dermatology
  Metronidazole disrupts bacterial and protozoal DNA by generating reactive oxygen species and damaging nucleic acids, leading to cell death.
• Metronidazole 250 (14 days) · University of Guarulhos · Infectious Disease
  Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material.

Phase 3 pipeline (1)

• Metronidazole 0.75% cream · Galderma R&D · Dermatology
  Metronidazole disrupts bacterial and protozoal DNA, leading to cell death and reduction of microorganisms associated with rosacea and other inflammatory skin conditions.